← Back to all trials
Not Yet Recruiting
NCT05707182
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study
Conditions: Prostate Cancer
Sex: Male
Ages: 18 Years – 89 Years
Phase: EARLY_PHASE1
Enrollment: 30
Sponsor: University of Alabama at Birmingham
Location: United States
Summary
The purpose of this study is to investigate the usefulness of PET/MRI with an investigational radioactive drug, 18F-rhPSMA-7.3,
and MRI contrast in evaluating patients with prostate cancer eligible for active surveillance.
This study is for imaging purposes only and is not a treatment study.
Eligibility Criteria
Inclusion Criteria:Men with biopsy-confirmed low risk or favorable intermediate risk prostate cancer who are scheduled to undergo multiparametric prostate MRI and confirmatory biopsy as per institutional active surveillance protocol.Exclusion Criteria:Biopsy-proven prostate cancer not eligible for active surveillance per institutional criteria.Current or prior treatment for prostate cancer.Suspected prostate cancer without histologic confirmation.Inability to undergo 3 Tesla prostate MRI due to claustrophobia and/or MRI- incompatible devices or MR incompatible metal implants.
Source: ClinicalTrials.gov (NCT05707182). StuddyBuddy aggregates publicly available trial information.
